Prostate Cancer | Norton Healthcare

Indication: Prostate Cancer

An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Proxalutamide (GT0918) in Subjects with Metastatic Castrate Resistant Prostate Cancer (mCRPC) who Failed Either Abiraterone or Enzalutamide

Metastatic Castrate Resistant

Sub-indication: Progressive disease despite hormonal treatment with abiraterone or enzalutamide, but not both. One line of chemotherapy is eligible

Line of Therapy: 2nd Line

Drug Study

Principal Investigator: Chandler Park, M.D.
Norton Cancer Institute

Sponsor: Suzhou Kintor Pharmaceuticals, Inc.

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.